首页> 外文期刊>European Journal of Pharmacology: An International Journal >Effect of telmisartan on the therapeutic efficacy of pitavastatin in high-fat diet induced dyslipidemic guinea pigs
【24h】

Effect of telmisartan on the therapeutic efficacy of pitavastatin in high-fat diet induced dyslipidemic guinea pigs

机译:替米沙坦对匹伐他汀在高脂饮食致血脂异常豚鼠中的治疗作用

获取原文
获取原文并翻译 | 示例
           

摘要

Angiotensin II-receptor blockers (ARBs), similar to HMG-CoA reductase inhibitors (statins), could improve lipid metabolism abnormalities. There might be some cross-talking pathways between statins and ARBs to produce additive beneficial effects on lipid metabolism in dyslipidemia. However, few studies investigate the effects of ARBs on the therapeutic efficacy of statins in dyslipidemia. The present study was designed to systematically evaluate the effects of telmisartan on the therapeutic efficacy of pitavastatin on lowering lipid level and reducing fat deposition by employing a dyslipidemia model, guinea pigs. 48 Male guinea pigs fed with high-fat diet were randomly grouped and treated with vehicle, telmisartan, pitavastatin or telmisartan/pitavastatin combinations. After treatment for eight weeks, telmisartan could significantly enhance the therapeutic efficacy of pitavastatin by extremely reducing body weight gain, weight of adipose tissue and adipocyte size. However, telmisartan/pitavastatin combinations could not further improve lipid levels on the basis of pitavastain, though single telmisartan markedly decreased triglyceride (TG) and slightly increased high density lipoprotein cholesterol (HDL-C). Moreover, telmisartan/pitavastatin combinations significantly upregulated the gene expression level of peroxisome proliferator-activated receptor (PPAR)-delta, but no effects on the expression of PPAR-alpha/gamma, leptin and adiponectin compared to monotherapy. Taken together, our studies provided new evidences that telmisartan has an additive beneficial influence on decreasing fat deposition and weight gain through PPAR-delta pathway but cannot enhance the therapeutic efficacy of pitavastatin on lowering lipid levels. The combinational administration of telmisartan and pitavastatin could be a potential therapeutic strategy for dyslipidemia related obesity and worthy of further investigation in obese animal models. (C) 2015 Elsevier B.V. All rights reserved.
机译:类似于HMG-CoA还原酶抑制剂(他汀类)的血管紧张素II受体阻滞剂(ARBs)可以改善脂质代谢异常。他汀类药物和ARB之间可能存在一些相互干扰的途径,以对血脂异常中的脂质代谢产生附加的有益作用。但是,很少有研究研究ARBs对他汀类药物在血脂异常中的治疗效果。本研究旨在通过采用血脂异常模型(豚鼠)来系统评估替米沙坦对匹伐他汀对降低血脂水平和减少脂肪沉积的治疗效果的作用。将高脂饮食的48只雄性豚鼠随机分组,并用赋形剂,替米沙坦,匹伐他汀或替米沙坦/匹伐他汀组合治疗。治疗八周后,替米沙坦可通过极大地减少体重增加,脂肪组织重量和脂肪细胞大小来显着提高匹伐他汀的治疗效果。然而,替米沙坦/匹伐他汀联合使用不能进一步提高匹他沙坦的血脂水平,尽管单个替米沙坦显着降低了甘油三酸酯(TG)并略微增加了高密度脂蛋白胆固醇(HDL-C)。此外,替米沙坦/匹伐他汀联合治疗可显着上调过氧化物酶体增殖物激活受体(PPAR)-δ的基因表达水平,但与单一疗法相比,对PPAR-α/γ,瘦素和脂联素的表达没有影响。两者合计,我们的研究提供了新的证据,替米沙坦对通过PPAR-δ途径减少脂肪沉积和体重增加具有附加的有益影响,但不能增强匹伐他汀对降低血脂水平的治疗效果。替米沙坦和匹伐他汀联合给药可能是血脂异常相关肥胖的潜在治疗策略,值得在肥胖动物模型中进行进一步研究。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号